What is Redfield?
Redfield Corp. is a specialized developer of the Infrared Coagulator, a non-surgical device engineered for the treatment of conditions including hemorrhoids, anal dysplasia, tattoo removal, hair transplant hemostasis, and chronic rhinitis. Leveraging over two decades of clinical application, their infrared coagulation (IRC) procedure is recognized for its patient-centric benefits: safety, efficacy, and rapid recovery. The IRC system is designed for ease of use, requiring minimal practitioner training, and benefits from favorable reimbursement from both Medicare and private insurance providers. This focus on accessible and effective treatment solutions positions Redfield as a key innovator in office-based medical procedures.
How much funding has Redfield raised?
Redfield has raised a total of $58K across 1 funding round:
Debt
$58K
Debt (2021): $58K with participation from PPP
What's next for Redfield?
The significant Series B/C stage funding indicates Redfield is poised for accelerated scaling. This capital injection is expected to fuel market penetration, further research and development for enhanced device capabilities, and potentially expand its therapeutic applications. The company's established clinical validation and strong reimbursement profile provide a solid foundation for future growth and market leadership in minimally invasive medical technologies.
See full Redfield company page
